BRÈVE

sur BIOMERIEUX (EPA:BIM)

BioMérieux Receives US FDA 510(k) Clearance for VITEK® REVEAL™ AST System

Graphique de l'évolution du cours de l'action BIOMERIEUX (EPA:BIM).

Marcy l’Étoile, France – June 21st, 2024 – bioMérieux has announced that its VITEK® REVEAL™ AST System has received U.S. FDA 510(k) clearance. This system provides antimicrobial susceptibility testing (AST) results directly from positive blood cultures, aiding clinicians in optimizing therapy for patients with bacteremic sepsis.

Worldwide, sepsis claims 11 million lives annually, with 1.3 million deaths linked to antibiotic-resistant bacteria. Rapid AST results are essential for improving patient care and supporting antimicrobial stewardship programs. These programs aim to reduce antimicrobial resistance, a global issue identified by the WHO.

The VITEK® REVEAL™ AST system, delivering results within 5.5-6 hours, is part of bioMérieux's strategy to combat sepsis and AMR. Acquired from Specific Diagnostics in 2022, this system integrates into bioMérieux’s diagnostic portfolio for bloodstream infections and sepsis.

This clearance allows the commercialization of VITEK® REVEAL™ in the U.S., following its Breakthrough Device Designation by the FDA in 2022. The system is also CE-marked in Europe under IVDD and IVDR regulations.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de BIOMERIEUX